FY232 facilities to g-B1073 mold remediation
Active Awarded Last action
- Contract number
- 75N91023F00014
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,955,434
Award facts
- Contract value 100% obligated
- $4,955,434.00 Current and potential, with all options
- Completion date 86% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $1,135,834 | |
| Other Administrative Action | $0 | |
| Original award | $3,819,600 |
About this award
This is a federal contract award to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract was awarded by the National Cancer Institute (NCI), a civilian agency, with a ceiling value of $4,955,434.00. The contract is a Delivery Order under a Cost Plus Fixed Fee pricing type, with an ultimate completion date of April 27, 2027.
The contract is for FY232 FACILITIES TO G-B1073 MOLD REMEDIATION services, and does not have a set-aside designation. Leidos Biomedical Research Inc. is the prime contractor, and through this award, will provide a broad range of research, development, and production services to the NCI, including facilities operations and maintenance, research and development activities, and specialized laboratory testing and analysis. The work will primarily be performed at Leidos Biomedical Research facilities in Fort Detrick and Frederick, Maryland.
Leidos Biomedical Research Inc. holds a single-award Indefinite Delivery Contract from the NCI, with a potential value of $6.6 billion over a 5-year base period, which establishes the company as a Federally Funded Research and Development Center (FFRDC) to provide a wide range of biomedical research and facilities support services to the NCI and other NIH institutes.
Quick answers
Who was awarded contract 75N91023F00014?
75N91023F00014 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2023.
How much is contract 75N91023F00014 worth?
The government has obligated $4,955,434 on 75N91023F00014.
Is contract 75N91023F00014 an order under another contract?
Yes. 75N91023F00014 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00014 competed?
The extent of competition for 75N91023F00014 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award